Industry News

STAAR Surgical reports $17.1 million in total sales for third quarter

Sales at STAAR Surgical totaled $17.1 million for the third quarter, an 7.8% increase from the same period in 2012, the company reported in a news release.

U.S. sales increased 7% and units grew 9%, with continuing signs that LASIK procedures are declining or flat.

For the 9-month period ending Sept. 27, sales increased to $53.3 million, a $6 million increase from the same period in 2012.

Third-quarter IOL sales totaled $5.3 million, a 12% decrease from the same period in 2012.

“The negative impact of foreign exchange was $809,000. Without the impact of foreign exchange, global IOL revenue would have increased 1% year over year,” the release said.

The Visian ICL accounted for 62.7% of total sales, compared with 57.4% of sales in the second quarter 2012. ICL sales totaled $10.7 million, an 18% increase from the second quarter 2012. This reflected a 15% increase in unit sales and a 2% price increase.

ICL revenues increased 9% in North America, 42% in Europe, 39% in the Middle East, 30% in Latin America and 10% in the Asia-Pacific region. Gains in the Europe-Middle East-Africa region were attributed to CentraFLOW technology with the ICL.

Revenues for the ICL increased 22% in China and decreased 5% in Japan.

Operating expenses totaled $11.9 million, an increase of 5% from the second quarter 2012. The increase stemmed from a manufacturing consolidation project.

Sales at STAAR Surgical totaled $17.1 million for the third quarter, an 7.8% increase from the same period in 2012, the company reported in a news release.

U.S. sales increased 7% and units grew 9%, with continuing signs that LASIK procedures are declining or flat.

For the 9-month period ending Sept. 27, sales increased to $53.3 million, a $6 million increase from the same period in 2012.

Third-quarter IOL sales totaled $5.3 million, a 12% decrease from the same period in 2012.

“The negative impact of foreign exchange was $809,000. Without the impact of foreign exchange, global IOL revenue would have increased 1% year over year,” the release said.

The Visian ICL accounted for 62.7% of total sales, compared with 57.4% of sales in the second quarter 2012. ICL sales totaled $10.7 million, an 18% increase from the second quarter 2012. This reflected a 15% increase in unit sales and a 2% price increase.

ICL revenues increased 9% in North America, 42% in Europe, 39% in the Middle East, 30% in Latin America and 10% in the Asia-Pacific region. Gains in the Europe-Middle East-Africa region were attributed to CentraFLOW technology with the ICL.

Revenues for the ICL increased 22% in China and decreased 5% in Japan.

Operating expenses totaled $11.9 million, an increase of 5% from the second quarter 2012. The increase stemmed from a manufacturing consolidation project.